According to the latest study from BCC Research, "Biologic Therapeutic Drugs: Technologies and Global Markets" is projected ...

Sanofi’s Sarclisa approved in the EU for the treatment of transplant-eligible newly diagnosed multiple myeloma  Approval based on GMMG-HD7 phase 3 study demonstrating that Sarclisa with VRd induction ...

Sanofi’s Sarclisa receives European approval to treat transplant-eligible newly diagnosed multiple myeloma: Paris Saturday, July 26, 2025, 09:00 Hrs [IST] Following the positive ...

Investors will focus on profits from asthma drug Dupixent and sales of Eylea HD when biotech giant Regeneron Pharmaceuticals, ...

Subtle differences in an mRNA sequence enables a ribosome to produce more or less of a certain protein. A new AI model called ...

Kling Bio has entered a partnership and licence option agreement with Sanofi to discover neutralising antibodies and epitopes.

Dutch privately-held biotech Kling Bio today announced it has entered into a collaboration and license option agreement with French pharma major Sanofi for the discovery of antibodies and epitopes ...

Kling Bio has announced a new collaboration and licence option agreement with Sanofi to accelerate the discovery of neutralising antibodies using its proprietary B cell platform, Kling-Select.

In July 2025, Inovio Pharmaceuticals conducted a Phase 1/2 trial to evaluate safety, immunogenicity and preliminary efficacy of INO-5401 and INO-9012 in combination with cemiplimab (REGN2810), with ...